151 related articles for article (PubMed ID: 9266936)
1. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study.
Matutes E; Meeus P; McLennan K; Catovsky D
Br J Haematol; 1997 Aug; 98(2):375-83. PubMed ID: 9266936
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Wheaton S; Tallman MS; Hakimian D; Peterson L
Blood; 1996 Feb; 87(4):1556-60. PubMed ID: 8608247
[TBL] [Abstract][Full Text] [Related]
4. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.
Dearden CE; Matutes E; Hilditch BL; Swansbury GJ; Catovsky D
Br J Haematol; 1999 Aug; 106(2):515-9. PubMed ID: 10460614
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
7. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
8. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration.
Thaler J; Grünewald K; Gattringer C; Ho AD; Weyrer K; Dietze O; Stauder R; Fluckinger T; Lang A; Huber H
Br J Haematol; 1993 May; 84(1):75-82. PubMed ID: 8338781
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall JF; Lederlin P; Harousseau JL; Blaise AM; Grosbois B; Morice P; Ghandour C; Castaigne S
Leukemia; 2003 Jan; 17(1):45-51. PubMed ID: 12529659
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease, its detection and significance in hairy-cell leukemia.
Zák P; Chrobák L; Dĕdic K
Acta Medica (Hradec Kralove); 1999; 42(3):85-8. PubMed ID: 10677893
[TBL] [Abstract][Full Text] [Related]
13. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients.
Rafel M; Cervantes F; Beltrán JM; Zuazu F; Hernández Nieto L; Rayón C; García Talavera J; Montserrat E
Cancer; 2000 Jan; 88(2):352-7. PubMed ID: 10640967
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
15. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up.
Seymour JF; Talpaz M; Kurzrock R
Leukemia; 1997 Jan; 11(1):42-7. PubMed ID: 9001417
[TBL] [Abstract][Full Text] [Related]
16. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
17. Pentostatin induces durable remissions in hairy cell leukemia.
Cassileth PA; Cheuvart B; Spiers AS; Harrington DP; Cummings FJ; Neiman RS; Bennett JM; O'Connell MJ
J Clin Oncol; 1991 Feb; 9(2):243-6. PubMed ID: 1988572
[TBL] [Abstract][Full Text] [Related]
18. Long term outcome of patients with hairy cell leukemia treated with pentostatin.
Ribeiro P; Bouaffia F; Peaud PY; Blanc M; Salles B; Salles G; Coiffier B
Cancer; 1999 Jan; 85(1):65-71. PubMed ID: 9921975
[TBL] [Abstract][Full Text] [Related]
19. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.
Mhawech-Fauceglia P; Oberholzer M; Aschenafi S; Baur A; Kurrer M; Von Rohr A; Hsu-Schmitz SF; Wagner B; Delacretaz F; Hurwitz N;
Arch Pathol Lab Med; 2006 Mar; 130(3):374-7. PubMed ID: 16519567
[TBL] [Abstract][Full Text] [Related]
20. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
